Faropenem

Faropenem is a potent and orally active beta-lactam antibiotic. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral proagent, faropenem medoxomil, for the research of respiratory tract infections[1][2].

Product Specifications

CAS Number

[106560-14-9]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/faropenem.html

Solubility

10 mM in DMSO

Smiles

O=C(C(N12)=C([C@@H]3OCCC3)S[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

Molecular Formula

C12H15NO5S

Molecular Weight

285.32

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Kristen N Schurek, et al. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007 Apr;5 (2) :185-98.|[2]Stanley C Gill, et al. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Antimicrob Agents Chemother. 2010 May;54 (5) :1678-83.